Form 4: Liquidia CMO Sells Shares for Tax Obligations Under Pre-Arranged Plan

Liquidia Corporation's Chief Medical Officer, Rajeev Saggar, sold 2,526 shares of common stock at $14.54 per share on July 21, 2025, to cover tax liabilities from restricted stock unit vesting.

Summary

• Rajeev Saggar, Chief Medical Officer of Liquidia Corp (LQDA), reported a transaction on July 21, 2025.
• The transaction involved the sale of 2,526 shares of common stock at a price of $14.54 per share.
• This sale was executed pursuant to a Rule 10b5-1 plan, which was adopted by Mr. Saggar on December 15, 2023.
• The purpose of the sale was to cover taxes associated with the settlement of restricted stock units (RSUs) that were initially granted on July 18, 2022.
• Following this transaction, Mr. Saggar beneficially owns 268,887 shares of common stock.
• The beneficial ownership includes 31,249 unvested RSUs from a January 11, 2023 grant, 35,307 unvested RSUs from a January 11, 2024 grant, and 71,780 RSUs from a January 11, 2025 grant (none of which have vested as of the filing date).
• It also includes 6,291 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale to cover tax obligations from RSU vesting, which is a common and non-discretionary event for executives and does not indicate a change in management's outlook on the company.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned and non-discretionary sale rather than a reactive decision based on new information.
• The sale's explicit purpose was to cover tax obligations related to RSU vesting, which is a common and routine event for executives and does not typically signal a lack of confidence in the company.

Negatives

• No inherent negatives are indicated by this specific transaction, as it is a routine tax-related sale.

Risks

• Intentional misstatements or omissions of facts constitute Federal Criminal Violations under 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
• These shares were sold to cover taxes associated with the settlement of restricted stock units that were initially granted to the Reporting Person on July 18, 2022.

Industry Context

This Form 4 filing details a routine insider transaction, specifically a sale of shares by a corporate officer to cover tax obligations arising from the vesting of restricted stock units. Such transactions are common across publicly traded companies, particularly those that utilize equity compensation plans for executives, and are generally not indicative of broader industry trends or competitive positioning.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for executive stock sales is a standard practice in the industry, designed to provide an affirmative defense against insider trading allegations by pre-scheduling transactions.
• Sales of shares to cover tax withholding upon RSU vesting are also a standard and expected component of executive compensation management across various industries, including biotechnology and pharmaceuticals, where equity awards are prevalent.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by an executive for tax purposes is a routine event and is unlikely to have a significant impact on the company's share price or long-term shareholder value.
• Employees: The filing details a standard aspect of executive compensation (RSU vesting and associated tax sales), which is common across companies with equity incentive plans.

Next Steps

• No specific future actions, events, or milestones are mentioned in this filing beyond the reported transaction.

Key Dates

Recommendation

The Form 4 details a routine, pre-planned sale of shares by a Chief Medical Officer to cover tax obligations related to RSU vesting. This type of transaction is common and typically does not reflect a change in management's confidence in the company's future prospects, thus it does not warrant a change in investment thesis based solely on this filing.

Keywords

Liquidia Corp, LQDA, Form 4, Insider Transaction, Stock Sale, Rajeev Saggar, Chief Medical Officer, Restricted Stock Units, RSU, 10b5-1 Plan, Tax Withholding, Executive Compensation